内源性大麻素与肝脏疾病。III. 内源性大麻素对免疫细胞的影响：对炎症性肝病的意义。
Endocannabinoids and liver disease. III. Endocannabinoid effects on immune cells: implications for inflammatory liver diseases.
作者信息
Pacher Pál, Gao Bin
机构信息
Laboratory of Physiological Studies, National Institutes of Health/NIAAA, 5625 Fishers Lane, MSC-9413, Bethesda, Maryland 20892-9413, USA.
出版信息
Am J Physiol Gastrointest Liver Physiol. 2008 Apr;294(4):G850-4. doi: 10.1152/ajpgi.00523.2007. Epub 2008 Jan 31.
Abstract
Recent studies have implicated dysregulation of the endocannabinoid system in various liver diseases and their complications (e.g., hepatitis, fibrosis, cirrhosis, cirrhotic cardiomyopathy, and ischemia-reperfusion), and demonstrated that its modulation by either cannabinoid 2 (CB(2)) receptor agonists or CB(1) antagonists may be of significant therapeutic benefits. This review is aimed to focus on the triggers and sources of endocannabinoids during liver inflammation and on the novel role of CB(2) receptors in the interplay between the activated endothelium and various inflammatory cells (leukocytes, lymphocytes, etc.), which play pivotal role in the early development and progression of inflammatory and other liver diseases.
摘要
最近的研究表明，内源性大麻素系统失调与各种肝脏疾病及其并发症（如肝炎、纤维化、肝硬化、肝硬化性心肌病和缺血再灌注）有关，并证明大麻素2（CB(2)）受体激动剂或CB(1)拮抗剂对其进行调节可能具有显著的治疗益处。本综述旨在关注肝脏炎症期间内源性大麻素的触发因素和来源，以及CB(2)受体在活化内皮细胞与各种炎症细胞（白细胞、淋巴细胞等）相互作用中的新作用，这些炎症细胞在炎症性和其他肝脏疾病的早期发展和进展中起关键作用。
相似文献
1
Endocannabinoids and liver disease. III. Endocannabinoid effects on immune cells: implications for inflammatory liver diseases.内源性大麻素与肝脏疾病。III. 内源性大麻素对免疫细胞的影响：对炎症性肝病的意义。
Am J Physiol Gastrointest Liver Physiol. 2008 Apr;294(4):G850-4. doi: 10.1152/ajpgi.00523.2007. Epub 2008 Jan 31.
2
Recent advances in the understanding of the role of the endocannabinoid system in liver diseases.内源性大麻素系统在肝脏疾病中的作用的研究进展。
Dig Liver Dis. 2011 Mar;43(3):188-93. doi: 10.1016/j.dld.2010.08.010. Epub 2010 Oct 8.
3
Endocannabinoids in liver disease.内源性大麻素在肝脏疾病中的作用。
Hepatology. 2011 Jan;53(1):346-55. doi: 10.1002/hep.24077.
4
Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver.内源性大麻素与肝脏疾病。一、肝脏中的内源性大麻素及其受体。
Am J Physiol Gastrointest Liver Physiol. 2008 Jan;294(1):G9-G12. doi: 10.1152/ajpgi.00467.2007. Epub 2007 Nov 1.
5
The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.靶向大麻素受体或调节内源性大麻素组织水平或作用的药物的治疗潜力。
AAPS J. 2005 Oct 24;7(3):E625-54. doi: 10.1208/aapsj070364.
6
Endocannabinoids, cannabinoid receptors and inflammatory stress: an interview with Dr. Pál [corrected] Pacher. Interviewed by Helene F. Rosenberg.
J Leukoc Biol. 2007 Dec;82(6):1390-2. doi: 10.1189/jlb.1307180.
7
Endocannabinoids signaling: Molecular mechanisms of liver regulation and diseases.内源性大麻素信号传导：肝脏调节和疾病的分子机制。
Front Biosci (Landmark Ed). 2016 Jun 1;21(7):1488-501. doi: 10.2741/4468.
8
Endocannabinoid overactivity and intestinal inflammation.内源性大麻素活性过高与肠道炎症
Gut. 2006 Oct;55(10):1373-6. doi: 10.1136/gut.2005.090472.
9
The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings.内源性大麻素系统作为肝脏疾病中的关键介质：新的见解和治疗新途径。
Br J Pharmacol. 2011 Aug;163(7):1432-40. doi: 10.1111/j.1476-5381.2011.01397.x.
10
The emerging role of the endocannabinoid system in cardiovascular disease.内源性大麻素系统在心血管疾病中的新作用。
Semin Immunopathol. 2009 Jun;31(1):63-77. doi: 10.1007/s00281-009-0145-8. Epub 2009 Apr 9.
引用本文的文献
1
Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches.当前治疗肝纤维化的研究：在重新利用 FDA 批准的药物和其他新兴方法之间。
J Pharm Pharm Sci. 2023 Nov 7;26:11808. doi: 10.3389/jpps.2023.11808. eCollection 2023.
2
Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years.内源性大麻素系统作为治疗靶点的利弊：30 年的经验教训。
Pharmacol Rev. 2023 Sep;75(5):885-958. doi: 10.1124/pharmrev.122.000600. Epub 2023 May 10.
3
Elucidating effects of environmental exposure using human-induced pluripotent stem cell disease modeling.利用人诱导多能干细胞疾病建模阐明环境暴露的影响。
EMBO Mol Med. 2022 Nov 8;14(11):e13260. doi: 10.15252/emmm.202013260. Epub 2022 Oct 26.
4
The protective effect of cannabinoid type II receptor agonist AM1241 on ConA-induced liver injury in mice via mitogen-activated protein kinase signalling pathway.大麻素受体 2 型激动剂 AM1241 通过丝裂原活化蛋白激酶信号通路对 ConA 诱导的小鼠肝损伤的保护作用。
Int J Immunopathol Pharmacol. 2021 Jan-Dec;35:20587384211035251. doi: 10.1177/20587384211035251.
5
The Role of Cannabinoids in the Setting of Cirrhosis.大麻素在肝硬化背景下的作用
Medicines (Basel). 2018 Jun 9;5(2):52. doi: 10.3390/medicines5020052.
6
What Can be Learned from the Time Course of Changes in Low-Frequency Stimulated Muscle?从低频刺激肌肉的变化时间进程中可以学到什么？
Eur J Transl Myol. 2017 Jun 24;27(2):6723. doi: 10.4081/ejtm.2017.6723.
7
Expression of the endocannabinoid receptors in human fascial tissue.内源性大麻素受体在人体筋膜组织中的表达。
Eur J Histochem. 2016 Jun 28;60(2):2643. doi: 10.4081/ejh.2016.2643.
8
New Developments on the Treatment of Liver Fibrosis.肝纤维化治疗的新进展
Dig Dis. 2016;34(5):589-96. doi: 10.1159/000445269. Epub 2016 Jun 22.
9
New therapies for hepatic fibrosis.肝纤维化的新疗法。
Clin Res Hepatol Gastroenterol. 2015 Sep;39 Suppl 1(0 1):S75-9. doi: 10.1016/j.clinre.2015.06.011. Epub 2015 Jul 20.
10
Elevated levels of endocannabinoids in chronic hepatitis C may modulate cellular immune response and hepatic stellate cell activation.慢性丙型肝炎中内源性大麻素水平升高可能会调节细胞免疫反应和肝星状细胞激活。
Int J Mol Sci. 2015 Mar 27;16(4):7057-76. doi: 10.3390/ijms16047057.
本文引用的文献
1
Liver: An organ with predominant innate immunity.肝脏：一个具有主要固有免疫的器官。
Hepatology. 2008 Feb;47(2):729-36. doi: 10.1002/hep.22034.
2
Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.内源性大麻素和大麻素受体在缺血再灌注损伤及预处理中的作用
Br J Pharmacol. 2008 Jan;153(2):252-62. doi: 10.1038/sj.bjp.0707582. Epub 2007 Nov 19.
3
Endocannabinoids and liver disease. II. Endocannabinoids in the pathogenesis and treatment of liver fibrosis.内源性大麻素与肝脏疾病。II. 内源性大麻素在肝纤维化发病机制及治疗中的作用
Am J Physiol Gastrointest Liver Physiol. 2008 Feb;294(2):G357-62. doi: 10.1152/ajpgi.00456.2007. Epub 2007 Nov 15.
4
CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration.CB2 大麻素受体激动剂可减弱肿瘤坏死因子-α 诱导的人血管平滑肌细胞增殖和迁移。
Br J Pharmacol. 2008 Jan;153(2):347-57. doi: 10.1038/sj.bjp.0707569. Epub 2007 Nov 12.
5
Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver.内源性大麻素与肝脏疾病。一、肝脏中的内源性大麻素及其受体。
Am J Physiol Gastrointest Liver Physiol. 2008 Jan;294(1):G9-G12. doi: 10.1152/ajpgi.00467.2007. Epub 2007 Nov 1.
6
Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity.CB1大麻素受体的药理学抑制可预防阿霉素诱导的心脏毒性。
J Am Coll Cardiol. 2007 Aug 7;50(6):528-36. doi: 10.1016/j.jacc.2007.03.057. Epub 2007 Jul 23.
7
CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion.CB2受体刺激可减弱肿瘤坏死因子-α诱导的人内皮细胞活化、单核细胞跨内皮迁移及单核细胞与内皮细胞的黏附。
Am J Physiol Heart Circ Physiol. 2007 Oct;293(4):H2210-8. doi: 10.1152/ajpheart.00688.2007. Epub 2007 Jul 27.
8
Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis.大麻素-2受体激动剂HU-308通过减轻氧化应激、炎症反应和细胞凋亡来保护肝脏免受缺血/再灌注损伤。
J Leukoc Biol. 2007 Dec;82(6):1382-9. doi: 10.1189/jlb.0307180. Epub 2007 Jul 25.
9
Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats.作用于CB1受体的内源性大麻素介导肝硬化大鼠体内的心脏收缩功能障碍。
Am J Physiol Heart Circ Physiol. 2007 Sep;293(3):H1689-95. doi: 10.1152/ajpheart.00538.2007. Epub 2007 Jun 8.
10
Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats.利莫那班可减轻肥胖的Zucker fa/fa大鼠的肥胖相关肝脂肪变性及代谢综合征特征。
Hepatology. 2007 Jul;46(1):122-9. doi: 10.1002/hep.21641.
Zotero 插件